vTv Therapeutics Expands At-The-Market Share Program Capacity

vTv Therapeutics ( (VTVT) ) has provided an update.

On May 13, 2026, vTv Therapeutics Inc. moved to expand its financial flexibility by filing a prospectus supplement with the SEC to increase the number of Class A common shares available under its previously announced at-the-market sales program. The company also filed a legal opinion from Dechert LLP to support the legality of the shares issuable under this program and to incorporate that opinion into its effective shelf registration statement, streamlining future share issuances and reinforcing compliance for potential capital raises.

The most recent analyst rating on (VTVT) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.

Spark’s Take on VTVT Stock

According to Spark, TipRanks’ AI Analyst, VTVT is a Neutral.

The score is primarily held down by weak financial performance (no consistent revenue, sizable losses, and sustained cash burn). Technicals are modestly supportive with the stock above major moving averages, but momentum is not strong. Valuation is constrained by loss-making results and no dividend, while recent corporate events provide a meaningful positive offset through cash runway visibility and partnership-driven funding potential.

To see Spark’s full report on VTVT stock, click here.

More about vTv Therapeutics

vTv Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies based on its small-molecule drug discovery platform. The company operates in the life sciences industry, with a market focus on novel treatments addressing unmet medical needs.

Average Trading Volume: 55,363

Technical Sentiment Signal: Hold

Current Market Cap: $134.2M

See more data about VTVT stock on TipRanks’ Stock Analysis page.